Patients should be observed following administration of Xolair®
CSU
In more than 700 Xolair®-treated patients enrolled in the phase III trials there were no cases of Xolair®-related anaphylaxis.1-3
Asthma
In patients with severe allergic asthma, anaphylaxis was rare (≥1/10,000 to <1/1,000) in previous clinical trials. Onset was usually within 2 hours of the first or subsequent injections, but may occur later. Patients should be informed that such reactions are possible.4